Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced

Transplantation

Volumn 70, Issue 1, 2000, Pages 136-143

  Van Besouw, Nicole M ^a   Van Der Mast, Barbara J ^a   De Kuiper, Petronella ^a   Smak Gregoor, Peter J H ^a   Vaessen, Lenard M B ^a   Ijzermans, Jan N M ^a   Van Gelder, Teun ^a   Weimar, Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HLA ANTIGEN CLASS 1; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 2; TETANUS TOXOID;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LYMPHOCYTE COUNT; MIXED LYMPHOCYTE CULTURE; MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034662242     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Versluis DJ, Wenting GJ, Derkx FHM, Schalekamp MADH, Jeekel J, Weimar W. Who should be converted from cyclosporine A to conventional immunosuppression in kidney transplantation, and why? Transplantation 1987; 44: 387.
2. Agarwal SK, Dash SC, Tiwari SC, et al. Results of conversion from triple-drug to double-drug therapy in living related renal transplantation. Transplantation 1995; 59: 27.
3. Kahn D, Ovnat A, Pontin AR, Swanepoel CR, Cassidy MJD. Long-term results with elective cyclosporine withdrawal at three months after renal transplantation: appropriate for living-related transplants? Transplantation 1994; 58: 1410.
4. Hollander AAMJ, Van Saase JLCM, Kootte AMM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610.
5. Tisone G, Angelico M, Palmieri G, et al. Immunosuppression without prednisone after liver transplantation is safe and associated with normal early graft function: preliminary results of a randomized study. Transplant Int 1998; 11: S267.
6. Sanfey H, Haussman G, Isaacs I, et al. Steroid withdrawal in kidney transplant recipients: is it a safe option? Clin Transplant 1997; 11: 500.
7. Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643.
8. Taylor DO, Bristow MR, O'Connell JB, et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 1996; 15: 1039.
9. Olivari MT, Jessen ME, Baldwin BJ, et al. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant 1995; 14:127.
10. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926.
11. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243.
12. Mazariegos GV, Ramos H, Shapiro R, Zeevi A, Fung JJ, Starzl TE. Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. Transplant Proc 1995; 27: 207.
13. Creemers P, Pascoe MD, Pontin AR, Kahn D. Rebound effect of the allogeneic T-cell response to donor and third-party lymphocytes after cyclosporine withdrawal in renal transplant recipients. Transplant Immunol 1998; 6: 261.
14. Goulmy E, Bittner K, Blokland E, et al. Renal transplant patients with steroid withdrawal evaluated longitudinally for their donor-specific cytotoxic T cell reactivity. Transplantation 1991; 52: 1083.
15. Beik AI, Higgins RM, Lam FT, Morris AG. Steroid withdrawal and donor-specific hyporeactivity after cadaveric renal allotransplantation on maintenance triple therapy. Nephrol Dial Transplant 1997; 12: 1949.
16. Van Emmerik NEM, Loonen EHM, Vaessen LMB, et al. The avidity, not the mere presence, of primed CTL for donor HLA class II antigens determines their clinical relevance after heart transplantation. J Heart Lung Transplant 1997; 16: 240.
17. Koning F, Kardol M, Van der Poel J et al. The influence of workshop monoclonal antibodies on CML, PLT, ADCC, and NK activity: functional studies with workshop antibodies. In: Reinhertz EL, ed. Proceedings of the Second International Workshop on Human Leukocyte Antigens. Heidelberg: Springer 1986: 189.
18. Bouma GJ, Van der Meer-Prins PMW, Van Bree FPMJ, Van Rood JJ, Claas FHJ. Determination of cytotoxic T-lymphocyte precursor frequencies using europium labelling as a non-radioactive alternative to labelling with chromium-51. Hum Immunol 1992; 35: 85.
19. Deacock S, Schwarer A, Batchelor R, Goldman J, Lechler R. A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2-producing T cells in human. J Immunol Methods 1992; 147: 83.
20. Schanz U, Roelen DL, Bruning JW, Kardol MJ, Van Rood JJ, Claas FHJ. The relative radioresistance of interleukin-2 production by human peripheral blood lymphocytes: consequences for the development of a new limiting dilution assay for the enumeration of helper T lymphocyte precursor frequencies. J Immunol Methods 1994; 169: 221.
21. Strijbosch LWG, Buurman WA, Does RJMM, Zinken PH, Groenewegen G. Limiting dilution analysis: experimental design and statistical analysis. J Immunol Methods 1987; 97: 133.
22. Reinsmoen NL, Matas AJ. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity. Transplantation 1993; 55: 1017.
23. Zanker B, Jooss-Rüdiger J, Franz HE, Wagner H, Kabelitz D. Evidence that functional deletion of donor-reactive T lymphocytes in kidney allograft recipients can occur at the level of cytotoxic T cells, IL-2-producing T cells, or both. Transplantation 1993; 56: 628.
24. Van Besouw NM, Vaessen LMB, Balk AHMM, Mochtar B, Claas FHJ, Weimar W. CsA therapy affects the direct and indirect antigen-presentation pathway in cardiac allograft recipients. Transplant Proc 1996; 28: 3135.
25. Herzog WR, Zanker B, Irschick E, Huber C, Franz HE, Wagner H, Kabelitz D. Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft. Transplantation 1987; 43: 384.
26. Wramner L, Olausson M, Söderström, Lindholm L, Rydberg L, Brynger H. Evidence of donor-specific cellular suppressor activity in donor-specific cell-mediated lympholysis unresponsiveness in renal transplant patients. Transplantation 1987; 44: 390.
27. Wramner L, Mjörnstedt L, Rydberg L, Olausson M. Cell-mediated immune responses in renal transplant recipients treated with cyclosporin and prednisolone with or without azathioprine. Scand J Immunol 1993; 37: 656.
28. DeBruyne LA, Renlund DG, Bishop DK. Evidence that human cardiac alllograft acceptance is associated with a decrease in donor-reactive helper T lymphocytes. Transplantation 1995; 59: 778.
29. Van Emmerik NEM, Vaessen LMB, Knoop CJ, et al. Kinetics of circulating cytotoxic T lymphocyte precursors that have a high avidity for donor antigens: correlation with the rejection status of the human cardiac allograft. Transplant Immunol 1998; 6: 153.
30. Smak Gregoor PJH, van Gelder T, van Besouw NM, van der Mast BK, IJzermans JNM, Weimar W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143.